Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., plans to transfer 38.5 million H-shares of Boan Biotechnology by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1] Group 1: Company Developments - Boan Biotechnology's stock rose nearly 5%, trading at HKD 9.12 with a transaction volume of HKD 358 million [1] - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating its antibody drug pipeline, technology platform, and production assets [1] - By 2025, Shandong Luye Pharmaceutical will hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1] Group 2: Strategic Importance - Boan Biotechnology plays a crucial role in Luye Pharma's dual-line R&D system, combining chemical and biopharmaceutical development [1]
港股异动 | 博安生物(06955)涨近5% 山东绿叶制药拟向Luye Geneora Holding进一步转让公司H股